Benralizumab (MEDI-563) is a subcutaneous injection therapy in advanced clinical testing as a treatment of COPD and asthma with sputum eosinophilia. Benralizumab (MEDI-563) is a subcutaneous injection therapy in advanced clinical testing as a treatment of COPD and asthma with sputum eosinophilia.